Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: Comment on the article by Yoo

被引：3
|
作者：
Daoussis, Dimitrios [1 ]
Andonopoulos, Andrew P. [1 ]
机构：
[1] Univ Patras, Sch Med, Patras Univ Hosp, Div Rheumatol,Dept Internal Med, Patras 26504, Greece
来源：
RHEUMATOLOGY INTERNATIONAL | 2011年 / 31卷 / 06期
关键词：
Systemic sclerosis; Scleroderma; Rituximab; Interstitial lung disease; B cells; Fibrosis; Skin thickening; Rheumatic diseases;
D O I：
10.1007/s00296-010-1485-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Several lines of evidence from basic research indicate that B cells may contribute to the pathogenesis of systemic sclerosis. Clinical studies as well have provided preliminary data pointing to the direction that B-cell depletion with rituximab might be a therapeutic option for patients with this debilitating disease.
引用
收藏
页码：841 / 842
页数：2
相关论文
共 50 条
  • [21] Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease
    Wollin, Lutz
    Distler, Joerg H. W.
    Denton, Christopher P.
    Gahlemann, Martina
    JOURNAL OF SCLERODERMA AND RELATED DISORDERS, 2019, 4 (03) : 212 - 218
  • [22] The role of antifibrotic therapies in the treatment of systemic sclerosis-associated interstitial lung disease
    Boleto, Goncalo
    Avouac, Jerome
    Allanore, Yannick
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2022, 14
  • [23] Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
    Chung, Jonathan H.
    Walker, Christopher M.
    Hobbs, Stephen
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2020, (160): : na
  • [24] Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease REPLY
    Distler, Oliver
    Gahlemann, Martina
    Maher, Toby M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (16): : 1596 - 1597
  • [25] Personalized Medicine for Systemic Sclerosis-Associated Interstitial Lung Disease
    Ma, Angela
    Montesi, Sydney B.
    CURRENT TREATMENT OPTIONS IN RHEUMATOLOGY, 2025, 11 (01)
  • [26] Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
    Athanasios Koutroumpas
    Athanasios Ziogas
    Ioannis Alexiou
    Georgia Barouta
    Lazaros I. Sakkas
    Clinical Rheumatology, 2010, 29 : 1167 - 1168
  • [27] Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
    Koutroumpas, Athanasios
    Ziogas, Athanasios
    Alexiou, Ioannis
    Barouta, Georgia
    Sakkas, Lazaros I.
    CLINICAL RHEUMATOLOGY, 2010, 29 (10) : 1167 - 1168
  • [28] Responses to exercise in systemic sclerosis-associated interstitial lung disease
    Donnelly, Ronan P.
    Smyth, Anita E.
    Mullan, Charles
    Riley, Marshall S.
    Nicholls, D. Paul
    CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING, 2023, 43 (04) : 253 - 262
  • [29] Systemic sclerosis-associated interstitial lung disease treated with tocilizumab
    Dauny, Vincent
    Borie, Raphael
    Forien, Marine
    Ghanem, Mada
    Palazzo, Elisabeth
    Jelin, Germain
    Dieude, Philippe
    Ottaviani, Sebastien
    INTERNAL MEDICINE JOURNAL, 2021, 51 (06) : 999 - 1000
  • [30] Pleuroparenchymal fibroelastosis in systemic sclerosis-associated interstitial lung disease
    Sari, Alper
    Onder, Omer
    Armagan, Berkan
    Bolek, Ertugrul Cagri
    Farisogullari, Bayram
    Bilgin, Emre
    Yardimci, Gozde Kubra
    Ariyurek, Macit
    Akdogan, Ali
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2022, 52 (01) : 83 - 88
12345